Kornimate/medical-research-clean huggingface dataset:
1,5 anhydroglucitol and 1,5 anhydroglucitol / glycated hemoglobin ratio as a potential biomarker for islet β-cell function and insulin resistance among patients with type 2 diabetes mellitus

Conditions: Diabetes Mellitus

Summary: hyperglycemia is a major risk factor for the micro- and macro-vascular complications of diabetes . lowering blood glucose levels has been shown to reduce the incidence of diabetes complications. therefore, there is a need for a simple surrogate biochemical marker for glycemic variability. glycated hemoglobin (hba1c) is the standard clinical measurement used to monitor glycemic status and is recommended to assess control of diabetes over the preceding 2-3 months. however, being a measure of mean glucose, it does not reflect glucose variability. it is well known that insulin secretion defects of islet β cells and/or tissue insensitivity to insulin are common pathophysiological mechanisms of diabetes mellitus (dm) . the elevation in the blood glucose level usually represents the degree of glucose metabolism disorder, which is generally assessed by glycated hemoglobin a1c ( hba1c) and indirectly reflects the extent of β-cell function damage . in the recent years, 1,5-anhydroglucitol (1,5-ag) has received attention as a short-term blood glucose index that reflects the average blood glucose level 1,5 ag reflects the average maximum blood glucose level during the past 1-2 weeks and is reported to be a more sensitive marker of glucose variability and postprandial hyperglycemia than hba1c, even for patients with prediabetes and for those with well or moderately controlled diabetes . (1,5 ag ) is structurally similar to glucose . due to this similarity, glucose inhibits renal reabsorption of 1,5 ag by competitive inhibition ,resulting in an inverse correlation of 1,5 ag with hyperglycemia . 1,5-ag levels are acting as an effective supplement to hba1c. additionally, previous study showed that 1,5-ag and hba1c had opposite curves with increasing blood glucose levels; specifically, with the increase in hba1c levels, 1,5-ag levels decreased significantly . therefore, we speculate a ratio of 1,5- ag / hb a1c in relation to islet β-cell function and insulin resistance. the aim of our study was to evaluate the role of 1,5 anhydroglucitol and 1,5 anhydroglucitol / hba1c ratio as a potential biomarker for islet β-cell function and insulin resistance among patients with type 2 diabetes .


Eligibility criteria:
inclusion criteria: * men and women aged 20 to 70 years old with controlled and uncontrolled type 2 dm. exclusion criteria: * : type 1 dm, * thyroid dysfunction, * chronic kidney disease, * chronic liver disease, * cancer patients, * cystic fibrosis, * acute and chronic infection and * pregnancy
β-glucan and exercise on musculoskeletal function in sarcopenic adults

Conditions: Sarcopenia

Summary: the investigators will conduct a randomized, double-blind, placebo-controlled study to investigate the effects of aureobasidium pullulans produced β-glucan and regular combined exercise on muscle strength, muscle mass, muscle function, and biomarkers in adults with relative sarcopenia for 12 weeks.

a previous human study has indicated that aureobasidium pullulans produced β-glucan may increase muscle mass and strength in the elderly. therefore, the investigators will conduct a randomized, double-blind, placebo-controlled study to investigate the effects of aureobasidium pullulans produced β-glucan on muscle strength, muscle mass, and muscle function, expanding the target population to adults aged 50 and older with relative sarcopenia, the safety of the compound are also evaluated. the investigators examine the peak torque/body weight at 60°/s knee extension, handgrip strength, skeletal muscle mass, physical performance, and metabolic parameters at baseline and 12 weeks of intervention. eighty adults were administered either 1,000 mg of aureobasidium pullulans produced β-glucan or a placebo each day for 12 weeks.

Eligibility criteria:
inclusion criteria: * \<110% of the standard lean body mass as measured using the body composition analyzer * body mass index (bmi) ranging from 18.5 to 30.0 kg/m2 * grip strength of the frequently used hand is based on the following age-specific standards: men in their 50s (less than 42 kg, women: less than 25.1 kg), men in their 60s (less than 38.5 kg, women: less than 24.1 kg), men 70 and older (less than 33.2 kg, women: less than 20.9 kg) * individuals with a short physical performance battery score of 9 or higher. exclusion criteria: * abnormal liver or renal function (more than twice the normal upper limit of the research institute) * uncontrolled diabetes mellitus (\>160 mg/dl of fasting blood sugar) * history of fracture during the previous year * uncontrolled hypertension (\>160/100 mmhg) * uncontrolled thyroid diseases. * history of serious cerebro-cardiovascular diseases or cancer such as angina or myocardial infarction within 6 months * history of any central bone fracture within 1 year * history of medication for psychiatric diseases such as severe depression, schizophrenia, and drug intoxication. * alcohol abuser * allergic reaction to aureobasidium pullulans produced β-glucan * those who participated in other drug clinical trials within 1 month from the screening date. * severe gastrointestinal symptoms such as heartburn and indigestion * those who are pregnant, lactating, or plan to become pregnant during the clinical trial * those who are judged to be unsuitable by the pi for other reasons
safety and efficacy of spd465 in adults with adhd

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: the purpose of the study is to evaluate how safe and how well spd465 works compared to placebo in adults with adhd. it is hypothesized that spd465 will achieve an extended duration of clinical benefit.


Eligibility criteria:
inclusion criteria: * primary diagnosis of adhd using dsm-iv-tr criteria (at least 6 of the 9 subtype criteria met) * baseline adhd-rs-iv score =\>24 * iq score of =\> 80 (using kaufman brief intelligence test) exclusion criteria: * bmi \ 30 kg/m2 * diagnosis of post traumatic stress disorder, psychosis, bipolar illness, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder * history of seizure disorder or a lifetime history of any seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or family history of tourette's disorder * history of uncontrolled hypertension or currently hypertensive * subjects who have taken atomoxetine (strattera) within 30 days prior to screening * current (or history within the last 12 months) of drug dependence or substance abuse disorder according to dsm-iv-tr criteria (excluding nicotine) * female subject is pregnant or lactating, less than 3 months post partum
volume guarantee ventilation in preterm infants with frequent episodes of hypoxemia

Conditions: Episodic Hypoxemia in Mechanically Ventilated Preterm Infants

Summary: preterm infants undergoing mechanical ventilation often present with respiratory instability which leads to fluctuations in ventilation and oxygenation. in conventional modes of mechanical ventilation used in these patients, the ventilator delivers breaths at a set rate and a constant peak inspiratory pressure. we have demonstrated that spontaneous episodes of hypoxemia in mechanically ventilated preterm infants are frequently triggered by a loss in end-expiratory lung volume followed by decrease in tidal volume. this is due to a reduction in respiratory system compliance and increase in airway resistance. volume guarantee ventilation is a mode of ventilation in which ventilator measures the exhaled tidal volume of each ventilator breath and automatically adjusts the peak inspiratory pressure to deliver the set tidal volume. we have previously shown that volume guarantee reduced the severity and duration of hypoxemia episodes during a period of 2 hours in preterm infants the study hypothesis is that volume guarantee ventilation will decrease the duration of episodes of hypoxemia when compared to conventional mechanical ventilation during routine clinical conditions and over longer periods of time. the objective of the study is to evaluate the effects of volume guarantee on the duration, severity and frequency of episodes of hypoxemia in mechanically ventilated preterm infants who present with frequent hypoxemia episodes in comparison to conventional ventilation over two periods of 24 hours each and under routine clinical conditions.


Eligibility criteria:
inclusion criteria: * born at less than 32 weeks of gestational age. * requiring mechanical ventilation on a mandatory ventilator rate greater than or equal to 20 per minute and receiving a mean tidal volume of at least 4 ml/kg. * presenting with 4 or more episodes of hypoxemia, defined as oxygen saturation less than 75%, in the 8 hours prior to the study. exclusion criteria: * major congenital anomalies. * hemodynamic instability requiring inotropes within 72 hours prior to the study * culture proven sepsis within 72 hours prior to the study. * diagnosis of pulmonary interstitial emphysema or pneumothorax within the 72 hours prior to the study.

Keywords: hypoxemia desaturation mechanical ventilation preterm infants volume guarantee ventilation
lal-ph-2000: treatment of acute lymphoblastic leukemia chromosome philadelphia positive

Conditions: Acute Lymphoblastic Leukemia

Summary: due to all ph+ patients should receive a different treatment, is proposed a therapeutical protocol with: intensification treatment of induction to increment the cr rate, allogenic transplantation in first cr, autologous transplantation follow by alfa interferon in patients cannot done allogenic transplantation.

remission induction: * vincristine (vcr): 1,5 mg/m2 i.v., days 1 and 8 * daunorubicin (dnr): 60 mg/m2 i.v., days 1 and 8. * prednisone (pdn): 60 mg/m2/day, i.v. or p.o., days 1 to 14 * l-asparaginase (l-asa): 10.000 ui/m2, i.v.days 5-7 and 11-13 results: 1. standard response: the induction treatment will be completed with the same drugs, changing l-asa to ara-c, during two more weeks 2 slow response. chemotherapy with mitoxantrone and high dose ara-c intrathecal chemotherapy: treatment with mitoxantrone, ara-c e hydrocortisone, days 1 and 22 consolidation treatment 1 start in two weeks after last dose of induction chemotherapy: * mercaptopurine (mp) 50 mg/m2, p.o., days 1-7, 28-35 and 56-63 * mitoxantrone (mtx): 3g/m2, i.v., in 24 hours, day 1, 28 and 56. * vm-26: 150 mg/m2 every 12 horas, i.v. (infusión 1 hora), días 14 y 42 * ara-c: 500 mg/m2 cada 12 hours, i.v., in 3 hours, days 14-15 and 42-43 * intrathecal treatment, days 28 and 56. 6.4. consolidation treatment 2 start in a week after last dose of mercaptopurine of previous cycle * dexamethasone (dxm): * 10 mg/m2 day, p.o. or i.v. days 1-14 * 5 mg/m2 day, p.o. or i.v., days 15-21 * vincristine (vcr): 1,5 mg/m2 i.v., days 1 and 8 and 15 * daunorubicin (dnr): 30 mg/m2 i.v., days 1, 2, 8 and 9. * cfm 600 mg/m2 day, i.v., days 1 and 15 * l-asparaginase (l-asa): 10.000 ui/m2, i.v.or im , days 1-3 and 15-17 * intrathecal treatment days 1 and 15. transplantation hematopoietic autologous transplantation with related donor, one or two months after last dose of consolidation treatment. hematopoietic autologous transplantation with unrelated donor, in patients younger than 45, and with ps 0-1 hematopoietic autologous transplantation in patients without related donor and without unrelated donor after six months searching

Eligibility criteria:
inclusion criteria: all bcr/abl+ patients age \< 65 years no previous treatment exclusion criteria: 1. other lla variability 2. previous history of coronary valvular, hypertensive cardiopathy illness 3. chronic hepatic illness 4. chronic respiratory insufficiency 5. renal insufficiency not caused by lla 6. severe neurological problems not caused by lla 7. severe affection of the performance status (grade 3-4 oms gradation) not caused by lla

Keywords: acute lymphoblastic leukemia chromosome philadelphia positive
frailty assesment in the congestive heart failure clinic

Conditions: Fragility Syndrome; Congestive Heart Failure

Summary: frailty is known as an independent risk factor for morbidity and mortality in older cardiac patients, including patients with congestive heart failure. it is an important factor taken into the cardiologists decision making in the clinic, and influences the intensity of follow up treatment, invasive intervention and the need to ensure a stronger social support system for the patient. frailty assessment is usually made subjectively by the cardiologist, known in the literature as eyeball testing. in this study the investigators will compare the cardiologists subjective eyeball testing to objective frailty assessment tests based on fried score and edmonton frail scale

elderly patients visiting the congestive heart failure clinic at meir medical center will be assessed for frailty twice. once in an "eyeball" test by their cardiologist at the clinic, and a second time in an objective test based on fried and edmonton frailty scores. the second subjective assessment will be made by geriatric and internal medicine physicians, and the cardiologist won't be aware of the results of the objective assessment. the results of both tests will be compared.

Eligibility criteria:
inclusion criteria: * patients an the meir congestive heart failure clinic. * age 70 and above * can sign an informed consent exclusion criteria: * patients admitted in the last two month
molecular characterization of perivascular epithelioid cell tumors

Conditions: Perivascular Epithelioid Cell Tumor, Malignant

Summary: perivascular epithelioid cell tumors (pecomas) are rare and are characterized by the expression of myomelanocytic markers. they are a complex family that includes angiomyolipomas, lymphangioleiomyomatoses and other soft tissue and visceral tumors. due to the low prevalence of these tumors, the natural history is unclear; furthermore, a molecular classification integrating clinical, pathological and molecular parameters has not been described to date.


Eligibility criteria:
inclusion criteria: * major patient (≥18 years) * minor patient (1 to 17 years old) * pecomas diagnosed in france between 01/01/1990 and 15/09/2019 and reviewed by a sarcoma referral pathologist exclusion criteria : * opposition of the patient (or the holders of parental authority) to participate in the study * biological tissue from a patient who does not meet all the inclusion criteria * classic triphasic angiomyolipoma or lymphangioleiomyomatosis * inability to provide informed information to the subject * patient under court protection * patient under guardianship or curatorship

Keywords: perivascular epithelioid cell tumors pecomas myomelanocytic markers angiomyolipomas lymphangioleiomyomatoses visceral tumors fluorescence in situ hybridization
study the effects of different doses of uk-369,003 in men with overactive bladder

Conditions: Urinary Bladder, Overactive

Summary: this is a 12 week study in which different doses of uk-369,003 will be administered to patients with a diagnosis of overactive bladder. patients will complete a series of questionnaires before treatment, during treatment and after treatment, to assess whether uk-369,003 has improved their symptoms of overactive bladder and erectile function.


Eligibility criteria:
inclusion criteria: * male subjects aged 18 years and above * documented clinical diagnosis of overactive bladder with urinary frequency \>= 8 times / 24 hours and number of urgency episodes \> 1 episode / 24 hours. exclusion criteria: * neurological diseases known to affect bladder function. * urinary tract infection.
computer-delivered screening & brief intervention for marijuana use in pregnancy

Conditions: Marijuana Use; Pregnancy

Summary: marijuana is by far the mostly commonly used illicit drug during pregnancy, and prenatal exposure to marijuana can have lasting negative effects. however, current answers to this problem are failing to reach most women who use marijuana while pregnant. this project will develop and begin testing two technology-based, highly practical interventions that could reduce the number of children who are prenatally exposed to marijuana.

there are at present no evidence-based interventions for marijuana use during pregnancy, despite its being by far the most commonly used illicit drug during pregnancy (particularly among african-american women), and despite growing evidence that it may have a range of long-term cognitive and neurobehavioral consequences. this r34 clinical trial planning grant therefore proposes the development and preliminary validation of two high- reach and mutually compatible technology-based interventions for marijuana use during pregnancy. the first, a theory-based, synchronous, and highly interactive computer-delivered brief intervention, will be based on an emerging knowledge base regarding key elements of efficacious technology-delivered interventions. the second intervention, a series of tailored text messages, will build on the rich literature regarding key tailoring elements. these interventions will be developed and refined with input from pregnant women who report active use of marijuana, as well as from health care providers. they will subsequently be tested-alone and in combination-in a pilot randomized trial involving 80 women actively using marijuana during pregnancy. this stage i pilot work would set the stage for a confirmatory stage ii trial. it would also produce the first high-reach brief interventions for marijuana use during pregnancy. if effective, these approaches could have a substantial population impact on marijuana use among pregnant women, with potential for lifelong improved outcomes for both mother and child.

Eligibility criteria:
inclusion criteria: * 18 to 40 years of age * 20 weeks or less gestation * intention to carry pregnancy to term * self-reported marijuana use in month before pregnancy * own a cell phone and willingness to receive text messages * gives consent to access medical records for collection of birth outcome data exclusion criteria: * frank cognitive impairment or psychosis * not able to communicate in english * not planning to deliver at a detroit medical center (dmc) hospital * previous or current participant in a study conducted by dr. ondersma * eunice kennedy shriver national institute of child health and human development (nichd) perinatal research branch participant.

Keywords: computerized brief intervention
epimedium prenylflavonoid (ep) extract for osteoporosis and cardiovascular disease

Conditions: Osteoporosis; Cardiovascular Disease

Summary: the primary objective of the trial is to develop epimedium prenylflavonoid (ep) extract as a pharmaceutical-quality intervention for post-menopausal osteoporosis and cardiovascular disease. there will be 3 cohorts of 10 healthy men each for the phase 1 study. in each cohort, 8 men will receive the epimedium capsules and 2 men will received the matched controls.

prenylflavonoids and its glycoside derivatives isolated from the traditional chinese medicine (tcm), epimedium, have potent estrogenic properties. the principal bioactive compounds in epimedium are the prenylflavonoids, icaritin, and their glycosylated derivatives which can enhance osteoblastic differentiation and mineralization, inhibits bone resorption, and induces apoptosis of osteoclasts. animal experiments indicate that icariin can prevent bone loss induced by ovariectomized (ovx) in rats, through its stimulatory effects on osteoblast growth and function, and inhibitory action on osteoclast cells. epimedium has also demonstrated significant cardiovascular benefits with positive actions on vascular reactivity, endothelial function and thrombosis in human subjects. notably, icariin, demonstrated a significant nitric oxide (no)-dependent vasorelaxation of precontracted coronary arterial rings with intact endothelium in a concentration-dependent manner, via the activation of endothelial nitric oxide synthase protein and no-cyclic guanidine monophosphate (cgmp) pathway. epimedium prenylflavonoids (ep) can prevent steroid-associated osteonecrosis in rabbit model and notably, reduce thrombosis incidence and shrink fat-cell-size significantly. this striking combination of properties highlights the immense potential in ep for osteoporosis and cardiovascular health.

Eligibility criteria:
inclusion criteria: * healthy men. exclusion criteria: * hepatitis b patients

Keywords: epimedium prenylflavonoids osteoporosis cardiovascular diseases phase 1 safety tolerability
comparison of fecal ribonucleic acid (rna) test with fecal occult blood test (fobt) for detecting colorectal cancer and adenoma

Conditions: Colorectal Cancer

Summary: colorectal cancer (crc) is the second common cause of death in the western world, and is very increasing in japan. fecal occult blood test (fobt) is used routinely for crc screening, which has been shown to reduce the incidence, morbidity, and mortality of crc. however, there is a need to develop a novel method to improve sensitivity. the investigators reported that fecal cox-2 assay, one of fecal rna test, is potentially useful for colorectal cancer screening (gastroenterology 127; 422-427, 2004). so the investigators planed to compare fecal rna test with fobt for detecting colorectal cancer and adenoma.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of colorectal cancer or adenoma * subjects with no abnormal findings of colon
pain management groups in occupational health settings

Conditions: Chronic Pain

Summary: this cluster randomized waiting-list controlled study will evaluate the effectiveness of pain management group activity organized by the oh on pain intensity and associated disability, and co-occurrence of mental or sleep problem in patients with chronic pain.

pain is very prevalent among the working population causing a considerable amount of work disability days. pain management group therapy has shown to have a significant effect on chronic pain. however, little is known of the effect of such therapy on work disability. there are especially very few studies prescribing the effectiveness of pain management groups provided by the occupational health service.

Eligibility criteria:
inclusion criteria: - chronic pain + increased risk of work disability (based on a screening survey) exclusion criteria: * a malignant disease such as cancer, or severe mental illness such as depression causing significant functional disability. * participating in another pain group elsewhere. * in the middle of a major life crises such as divorce.

Keywords: pain management chronic pain health services occupational health
prophylactic effects of ondansetron, ramosetron, and palonosetron on patient-controlled analgesia related nausea and vomiting after urologic laparoscopic surgery

Conditions: Laparoscopic Marsupialization of Renal Cyst

Summary: the aim of this prospective randomized controlled study was to compare the prophylactic effects of intravenous single dose of ondansetron, ramosetron, and palonosetron on pca-related nausea and vomiting after urologic laparoscopic surgery.


Eligibility criteria:
inclusion criteria: * asa i or ii * patients aged (20-65 yr) undergoing laparoscopic nephrectomy * patients who want a patient-controlled iv analgesia (iv-pca) exclusion criteria: * history of allergy or hypersensitivity to 5-ht3 antagonist * history of severe postoperative nausea/vomiting * prolonged qt interval on preoperative ekg * hypokalemia, hypomagnesemia * intestinal obstruction * pregnant female or breast feeding mother